This bill amends the General Laws to establish a framework for pharmacists to prescribe and dispense FDA-approved tobacco cessation drug therapies. It introduces a new section, 5-19.1-37, which outlines the qualifications for pharmacists, including the completion of tobacco cessation education approved by the state board of pharmacy and the requirement to refer high-risk patients to their primary care providers. The bill defines a "qualified patient" as someone who is at least 18 years old, willing to participate in a structured cessation program, and educated on the potential adverse effects of the medications.

Additionally, the bill mandates that all group health insurance contracts and medical expense policies provide coverage for tobacco cessation drug therapies and pharmacists' services starting January 1, 2026. This requirement applies to various types of health insurance carriers, including nonprofit medical service corporations and health maintenance organizations. The legislation ensures that pharmacists are recognized as providers within health insurance networks, allowing them to deliver services without unnecessary supervision or referral requirements. Furthermore, it specifies that notification of patient screening, prescription records, and follow-up care plans must be provided to the patient's primary care provider within five business days following the prescribing of a tobacco cessation product. Overall, the bill aims to enhance access to tobacco cessation therapies and support public health initiatives to reduce tobacco use.